Annexon Inc Dossier - Source-backed chat

Annexon Inc

ANNXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.14

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.23Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $801.9M

Enterprise Value $602.6M

Shares Outstanding 204.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Annexon, Inc. is a clinical-stage biopharmaceutical company uniquely positioned to capture significant value in 2026 through its targeted classical complement platform. By focusing on C1q inhibition, Annexon stops neuroinflammation at its source, addressing severe autoimmune, ophthalmic, and neurodegenerative diseases. The company's investment thesis is anchored by two late-stage registrational programs: tanruprubart (ANX005) for Guillain-Barré Syndrome (GBS) and vonaprument (ANX007) for Geographic Atrophy (GA). With an EMA MAA already under review and a planned U.S. BLA submission in 2026 for tanruprubart, alongside pivotal Phase 3 ARCHER II data for vonaprument expected in Q4 2026, Annexon is entering a catalyst-rich execution phase. Backed by a solid cash runway of $225 million extending into H2 2027, the company offers an asymmetric risk-reward profile for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$14.71

High · most bullish analyst$27.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The bear case is triggered by clinical or regulatory setbacks. If the FDA requests additional clinical trials for tanruprubart beyond the FORWARD study, the U.S. BLA submission is delayed into 2027 or later. More critically, if vonaprument's Phase 3 ARCHER II trial fails to show statistically significant vision preservation in Q4 2026, the ophthalmology franchise loses its competitive edge. Setbacks would accelerate cash burn, force highly dilutive equity raises under the expanded share authorization, and depress the stock toward the analyst floor of $7.00.

Base CaseCentral scenario

$14.7155%

Matches the consensus mean

The base case assumes tanruprubart successfully progresses through regulatory channels, with the EMA review advancing smoothly and the U.S. BLA submitted in late 2026. Vonaprument's Phase 3 ARCHER II trial meets its primary endpoint of preserving visual acuity in GA, confirming the neuroprotective benefits observed in Phase 2. The company maintains its cash runway into H2 2027, utilizing its newly expanded authorized share headroom (increased to 500 million shares) to secure non-dilutive partnerships or opportunistic capital. The stock converges toward the consensus analyst target of $14.00 to $16.00.

Bull CaseUpside scenario

$27.0025%

The bull case assumes flawless execution across both lead programs. Tanruprubart receives EMA approval and subsequent FDA approval in GBS, establishing it as the first-in-class targeted therapy for a disease with no approved disease-modifying treatments, driving peak sales toward $1.2 billion. Simultaneously, vonaprument's Phase 3 ARCHER II trial delivers robust, statistically significant vision preservation data in Q4 2026, positioning it as a highly differentiated, superior alternative to existing GA therapies that only slow lesion growth. Rapid market uptake and strategic commercial partnerships propel the stock toward the high analyst target of $27.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class therapeutic mechanism targeting C1q to halt classical complement-mediated neuroinflammation at its upstream source.
Tanruprubart is positioned to become the first approved disease-modifying therapy for Guillain-Barré Syndrome (GBS), a severe neuromuscular emergency.
Vonaprument is the only geographic atrophy (GA) candidate designed to preserve functional vision (visual acuity) rather than merely slowing lesion expansion.
Strong balance sheet with $225 million in cash and short-term investments as of March 31, 2026, providing a runway into the second half of 2027.
Diversified pipeline with oral small molecule ANX1502 advancing in cold agglutinin disease (CAD) and other autoimmune indications.

Key Investment Risks

Binary clinical trial risk associated with the upcoming Phase 3 ARCHER II topline data readout in Q4 2026.
Regulatory execution risks, including potential FDA requests for additional Western clinical data for tanruprubart beyond the FORWARD study.
Commercialization risks in establishing specialty sales forces for GBS and competing against established complement giants in the GA market.
Continued high cash burn rate typical of late-stage biopharmaceutical companies, with an accumulated deficit of $961.5 million as of Q1 2026.

Thesis Invalidation Triggers

Failure of vonaprument (ANX007) to meet its primary endpoint of visual acuity preservation in the Phase 3 ARCHER II trial.
A major regulatory setback, such as a Refusal to File (RTF) or Complete Response Letter (CRL) from the FDA or EMA for tanruprubart in GBS.
Safety signals or serious adverse events emerging from the ongoing FORWARD open-label study or the ANX1502 POC trial.
Severe capital constraints forcing highly dilutive financing before achieving commercial product revenues.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.